VBCR - December 2012, Volume 1, No 6 - FDA Approvals, News & Updates

In November 2012, the US Food and Drug Administration (FDA) approved tofacitinib (Xeljanz; Pfizer) for adult patients with moderate-to-severe rheumatoid arthritis (RA) who do not adequately respond to or are intolerant of methotrexate. Tofacitinib is a Janus kinase inhibitor that is administered orally, at a dosage of 5 mg twice daily. The drug was approved under the FDA’s priority review process.

Tofacitinib was evaluated in 7 clinical trials with adult patients with moderate-to-severe RA. In all of the trials, the patients receiving tofaci­tinib showed improved clinical re­sponse and physical functioning compared with placebo.

“Xeljanz provides a new treatment option for adults suffering from the debilitating disease of RA who have had a poor response to methotrexate,” said Badrul Chowdhury, MD, PhD, Director of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.

The most common adverse effects included upper respiratory tract infections, headache, diarrhea, and inflammation of the nasal passages as well as the upper part of the pharynx.

In the clinical trials, tofacitinib was associated with an increased risk of serious infections, including opportunistic infections, as well as tuberculosis, some cancers, and lymphoma. Therefore, the medication carries a Boxed Warning related to these potential risks. In addition, treatment with tofacitinib is associated with increased cholesterol levels and liver enzymes, as well as decreased blood counts.  

The FDA approved tofacitinib with a Risk Evaluation and Mitigation Strategy program requiring safety information on the drug’s package insert label to advise patients and inform healthcare providers about the serious risks associated with the drug.

Furthermore, the FDA is requiring the drug’s manufacturer to conduct a postmarketing study to evaluate the long-term effects in heart disease, cancer, and serious infections. This study will evaluate 2 doses of tofacitinib and will include a group of patients on another approved treatment to serve as a comparison. The manufacturer also will provide additional data on treatment with the 10-mg dose in patients with RA. (November 6, 2012)

Related Items
FDA News - December 2017
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in FDA Approvals, News & Updates
FDA News - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in FDA Approvals, News & Updates
Scott Gottlieb, MD, Appointed as New FDA Commissioner
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA Approvals, News & Updates
New Drugs Approved for Giant-Cell Arteritis and Moderate-to-Severe Rheumatoid Arthritis
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA Approvals, News & Updates
FDA Releases Draft Guidances on Sharing Healthcare Economic Information, Industry Communication Regulations
Leslie Wyatt
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in FDA Approvals, News & Updates
FDA News - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in FDA Approvals, News & Updates
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
Web Exclusives published on December 15, 2016 in FDA Approvals, News & Updates, In the News
FDA News - November 2016
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in FDA Approvals, News & Updates
Abuse-Deterrent Oxycodone Extended-Release Capsules Approved for Chronic Pain
Web Exclusives published on November 7, 2016 in FDA Approvals, News & Updates, In the News
FDA News - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in FDA Approvals, News & Updates
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology